Alpha-glucosidase activity inhibitory component in Yeyanghe and its preparation method and application

Abstract

The invention relates to an alpha-glucosidase activity inhibition component in habenaria ciliolaris kranzl, and a preparation method and application of the alpha-glucosidase activity inhibition component, belonging to the fields of chemistry and chemical engineering. The preparation method comprises the following steps: crushing the habenaria ciliolaris kranzl until the particle size of the crushed habenaria ciliolaris kranzl is 420-580mu m; mixing an extracting agent and the crushed habenaria ciliolaris kranzl according to a first solid-liquid ratio of (20-100g): (500-6000mL), and extracting for 20-50h to obtain a crude habenaria ciliolaris kranzl extract; filtering, collecting supernatant, and concentrating to obtain extractum of the crude extract; dispersing the extractum of the crude extract into water according to a second solid-liquid ratio of 1g: (1-6mL), carrying out gradient elution on a sample solution in a macroporous adsorption resin chromatography column, and collecting and concentrating methyl alcohol elution peak with activity to obtain the activity inhibition component. The method is simple and easy to operate. The alpha-glucosidase activity inhibition component prepared by the method has stronger alpha-glucosidase inhibition activity, and has a better inhibiting effect especially for the activity of maltase.

Description

technical field

[0001] The invention relates to the field of chemistry and chemical engineering, and in particular to an α-glucosidase activity inhibiting component in Yeyanghe and its preparation method and application. Background technique

[0002] Diabetes mellitus (DM) is a disease of endocrine and metabolic disorders caused by insufficient insulin content in human blood. It is characterized by increased blood sugar and urine sugar, which can lead to damage to multiple systems and organs. Leading cause of cerebrovascular disease, blindness, amputations and renal failure. A variety of hypoglycemic drugs have been developed clinically, such as insulin secretion promoters that improve glucose tolerance and insulin response levels, agents that improve glucose metabolism, aldose reductase inhibitors that prevent and delay the occurrence of symptoms, and insulin sensitizers. Among them, α-glucosidase inhibitors have become a hot spot in the development and research of oral hy...

Images